Home > Publications Database > Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder > print

001     163375
005     20240617134627.0
024 7 _ |a pmc:PMC8600613
|2 pmc
024 7 _ |a 10.1016/S1474-4422(21)00176-9
|2 doi
024 7 _ |a 1474-4422
|2 ISSN
024 7 _ |a 1474-4465
|2 ISSN
024 7 _ |a altmetric:110133634
|2 altmetric
024 7 _ |a pmid:34302789
|2 pmid
037 _ _ |a DZNE-2022-00138
082 _ _ |a 610
100 1 _ |a Miglis, Mitchell G
|b 0
245 _ _ |a Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder
260 _ _ |a London
|c 2021
|b Lancet Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718624736_25686
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a REM Sleep Behavior Disorder: complications
|2 MeSH
650 _ 2 |a REM Sleep Behavior Disorder: diagnosis
|2 MeSH
650 _ 2 |a Synucleinopathies: diagnosis
|2 MeSH
650 _ 2 |a Synucleinopathies: etiology
|2 MeSH
650 _ 2 |a alpha-Synuclein
|2 MeSH
700 1 _ |a Adler, Charles H
|b 1
700 1 _ |a Antelmi, Elena
|b 2
700 1 _ |a Arnaldi, Dario
|b 3
700 1 _ |a Baldelli, Luca
|b 4
700 1 _ |a Boeve, Bradley F
|b 5
700 1 _ |a Cesari, Matteo
|b 6
700 1 _ |a Dall'Antonia, Irene
|b 7
700 1 _ |a Diederich, Nico J
|b 8
700 1 _ |a Doppler, Kathrin
|b 9
700 1 _ |a Dušek, Petr
|b 10
700 1 _ |a Ferri, Raffaele
|b 11
700 1 _ |a Gagnon, Jean-François
|b 12
700 1 _ |a Gan-Or, Ziv
|b 13
700 1 _ |a Hermann, Wiebke
|0 P:(DE-2719)2814194
|b 14
|u dzne
700 1 _ |a Högl, Birgit
|b 15
700 1 _ |a Hu, Michele T
|b 16
700 1 _ |a Iranzo, Alex
|b 17
700 1 _ |a Janzen, Annette
|b 18
700 1 _ |a Kuzkina, Anastasia
|b 19
700 1 _ |a Lee, Jee-Young
|b 20
700 1 _ |a Leenders, Klaus L
|b 21
700 1 _ |a Lewis, Simon J G
|b 22
700 1 _ |a Liguori, Claudio
|b 23
700 1 _ |a Liu, Jun
|b 24
700 1 _ |a Lo, Christine
|b 25
700 1 _ |a Ehgoetz Martens, Kaylena A
|b 26
700 1 _ |a Nepozitek, Jiri
|b 27
700 1 _ |a Plazzi, Giuseppe
|b 28
700 1 _ |a Provini, Federica
|b 29
700 1 _ |a Puligheddu, Monica
|b 30
700 1 _ |a Rolinski, Michal
|b 31
700 1 _ |a Rusz, Jan
|b 32
700 1 _ |a Stefani, Ambra
|b 33
700 1 _ |a Summers, Rebekah L S
|b 34
700 1 _ |a Yoo, Dallah
|b 35
700 1 _ |a Zitser, Jennifer
|b 36
700 1 _ |a Oertel, Wolfgang H
|0 P:(DE-2719)9000908
|b 37
|u dzne
773 _ _ |a 10.1016/S1474-4422(21)00176-9
|g Vol. 20, no. 8, p. 671 - 684
|0 PERI:(DE-600)2079704-7
|n 8
|p 671 - 684
|t The lancet / Neurology
|v 20
|y 2021
|x 1474-4422
856 4 _ |u https://pub.dzne.de/record/163375/files/DZNE-2022-00138_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/163375/files/DZNE-2022-00138_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:163375
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2814194
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 37
|6 P:(DE-2719)9000908
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-09
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET NEUROL : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a IF >= 50
|0 StatID:(DE-HGF)9950
|2 StatID
|b LANCET NEUROL : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21